Skip to main content

Table 2 Effect of thalidomide and analogs on serum cytokine levels in LPS treated mice

From: Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity

Compound

Amount (mg/kg)

Cytokine Level (ng/ml)

TNFα

IL-10

LPS (5 mg/kg) +:

   

None (control)

4.5 ± 1.5

19.9 ± 5.1

Thalidomide

1

2.2 ± 0.7a

25.6 ± 5.6

 

10

2.1 ± 0.8a

25.3 ± 5.6

 

100

1.7 ± 0.5a

32.4 ± 4.8a

CC-1069

1

3.1 ± 1.0

25.7 ± 2.1

 

10

1.5 ± 0.2a

28.7 ± 4.1a

 

100

0.6 ± 0.3a

44.8 ± 5.6a

CC-1104

1

4.9 ± 0.8

13.0 ± 0.3

 

10

3.2 ± 0.3

16.7 ± 3.8

 

100

1.9 ± 0.4a

17.9 ± 2.3

CC-1115

1

2.7 ± 0.9

26.6 ± 2.8

 

10

2.7 ± 0.4

29.9 ± 2.5a

 

100

1.6 ± 0.4a

32.4 ± 2.4a

  1. Concentration of cytokines in serum after LPS injection was evaluated by ELISA. Drugs were given i.p. 2 hr before i.p. administration of LPS. Blood samples were collected 1.5 hr later. Results are expressed as the mean ± SD of three to five experiments (four mice per group in each experiment).
  2. aDenotes significant (p < 0.05) difference compared with control values.